Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Dynavax Technologies Fell Again Today

By Cory Renauer - Jul 22, 2019 at 5:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It took another tumble despite enthusiastic analyst upgrades earlier this month.

What happened

Shares of Dynavax Technologies ( DVAX -3.65% ), a biopharmaceutical company struggling to launch a next-generation hepatitis B vaccine, reached a new low today. Despite investment-bank analyst upgrades earlier this month, the stock fell 8.5% on Monday.

So what

After its attempt to become an oncology drug developer didn't work out, Dynavax recently fell back to plan A. That plan involves circling wagons around Heplisav-B, a two-shot vaccine that works as well as the old vaccine -- which requires three shots spread over a longer time frame.

A downward-sloping chart drawn with chalk

Image source: Getty Images.

Cantor Fitzgerald recently raised some eyebrows by calling the stock a potential five-bagger, citing the need for increased compliance with hepatitis B vaccination -- too many people don't come back for a third dose. After taking a weekend to consider the chances that Dynavax will be able to reach profitability before running out of money again, investors were far less enthusiastic.

Now what

After losing $39.7 million during the first three months of the year, Dynavax finished March with $183 million in cash and securities. If a slimmed-down staff focused on selling Heplisav-B can boost sales of the vaccine from an annualized $23 million to around $100 million in a year or two, Dynavax could start making ends meet.

At recent prices, Dynavax sports a $218 million market cap. That means the stock would skyrocket if the Heplisav-B vaccine approaches its potential. Given the company's track record, though, it probably isn't worth the risk.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
DVAX
$15.56 (-3.65%) $0.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
656%
 
S&P 500 Returns
144%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.